Back to top

BridgeBio Pharma (BBIO) Receives a Buy from Mizuho Securities

In a report released yesterday, Salim Syed from Mizuho Securities maintained a Buy rating on BridgeBio Pharma, with a price target of $96.00. Accor...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

BridgeBio Pharma, Inc. (BBIO)